Clinical Trials Logo

Clinical Trial Summary

To address the challenges of isolating and analyzing rare cells, this study aims to validate the instrumentation, the test protocols, and the analysis of patient's outcome to show the instrument's capability to reproducibly and accurately detect CTCs in cancer patients. In order to facilitate the validation process, investigators will only focus on metastatic patients for whom CTCs supposedly present at higher abundance. Investigators propose to enroll cohorts of metastatic breast cancer patients. Blood samples will be collected from these patients before they start any new line of therapy as determined by their doctors. The specific aims are to isolate, enumerate and analyze the number and/or molecular information of circulating tumor cells in patient blood using microfluidic chip-based sorting, imaging, and molecular profiling techniques. Investigators will use this study to optimize diagnostic instrumentation, test blood processing protocols and CTC analysis algorithm. During this study investigators will collect patients' clinical information related to cancer, as well as the patients' survival status to validate the system's prognosis ability.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02904135
Study type Observational
Source MiCareo Taiwan Co., Ltd.
Contact
Status Completed
Phase N/A
Start date February 2014
Completion date December 2016

See also
  Status Clinical Trial Phase
Completed NCT03928210 - Digoxin Induced Dissolution of CTC Clusters Early Phase 1
Completed NCT02904161 - Detection of Circulating Tumor Cells in Peripheral Blood From Healthy Volunteers and Patients With Cancer N/A